Proclara Biosciences to Present at the Cowen and Company 38th Annual Health Care Conference

CAMBRIDGE, Mass.--()--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that Proclara’s Chief Executive Officer, Suzanne Bruhn, Ph.D., will present a company overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 1:30 p.m. ET in Boston, Mass.

About Proclara Biosciences

Proclara Biosciences is a biotechnology company advancing product candidates developed based on its proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the GAIM technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and orphan systemic amyloidoses. Proclara has developed a pipeline of drug candidates that use GAIM to target the common amyloid protein conformation, dissociating and preventing the formation of misfolded protein assemblies, and blocking the cell-to-cell transmission of toxic aggregates. The company’s lead program NPT088 is currently being evaluated in a Phase 1b trial for Alzheimer’s disease.

For more information, please visit proclarabio.com.

Contacts

Media:
Ten Bridge Communications
Sarah Sutton, 518-932-3680
sarah@tenbridgecommunications.com
or
Investor Relations:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com

Release Summary

Proclara Biosciences announced that CEO, Suzanne Bruhn, Ph.D., will present a company overview at the Cowen and Company Annual Health Care Conference.

Contacts

Media:
Ten Bridge Communications
Sarah Sutton, 518-932-3680
sarah@tenbridgecommunications.com
or
Investor Relations:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com